에피스 스토리

에피스 스토리

영문으로 운영되고 있는 삼성바이오에피스 SNS에 포스팅된 글입니다.

트위터 링크드

2024/10/12 Samsung Bioepis Wins ‘Company of the Year, Asia-Pacific’ at the Global Generics & Biosimilars Awards 2024

Once again, for the second consecutive year, Samsung Bioepis takes home the trophy for ‘Company of the Year, Asia-Pacific’ at the Global Generics & Biosimilars (GGB) Awards 2024, held in Milan, Italy on October 9th!  This marks the company’s fourth recognition for its consistent leadership in biosimilars and its unwavering commitment to advancing access to innovative treatments for patients worldwide.  

Samsung Bioepis has been recognized for numerous approvals and market access milestones over the past year including the U.S. Food and Drug Administration (FDA) approvals of three biosimilar products – aflibercept, eculizumab, ustekinumab – and interchangeability designation of the low concentration vial and pre-filled syringe adalimumab biosimilar. Furthermore, company’s eculizumab biosimilar gained an indication expansion in Europe to atypical hemolytic uremic syndrome (aHUS) from existing paroxysmal nocturnal hemoglobinuria (PNH) indication based on the principle of extrapolation, supported by the totality-of-the-evidence.

This year, the company has also been shortlisted as finalists for ‘Company of the Year,’ ‘Biosimilar Initiative of the Year,’ and ‘Regulatory Achievement of the Year.’ Previously, Samsung Bioepis won the GGB Awards for ‘Company of the Year, Asia-Pacific’, and ‘Regulatory Achievement of the Year’ in 2023, ‘Company of the Year, Asia-Pacific’ category in 2022 and ‘Biosimilar Initiative of the Year’ category in 2020. 

The ‘Global Generics & Biosimilars Awards’ are presented annually by the international publishing company Citeline. This year, the event was held in Milan, Italy on October 9, to celebrate the greatest achievements and innovations across the development, authorization, marketing and distribution of global off-patent pharmaceuticals and to discuss future opportunities and challenges and shine a light on the companies and individuals driving positive change.
more
SAMSUNG BIOEPIS

확인 취소
레이어 팝업 닫기